Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy

Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Aichler, Michaela, Motschmann, Martin, Jütting, Uta, Luber, Birgit, Becker, Karen, Ott, Katja, Lordick, Florian, Langer, Rupert, Feith, Marcus, Siewert, Jörg Rüdiger, Walch, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196151/
https://www.ncbi.nlm.nih.gov/pubmed/25216514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196151/
https://www.ncbi.nlm.nih.gov/pubmed/25216514

Ejemplares similares